Who we are
We transform the lives of airways diseases patients, developing products that help patients to breathe more easily.
Find out more
We are a uniquely positioned formulation and device partnering expert with clear strategic priorities.
We are resolutely pursuing our vision to be the industry-leading inhaled drug device development specialist.
The airways diseases market is worth $40bn worldwide and Vectura is well placed to benefit from changing market dynamics.
Our refined pipeline achieves our investment objectives and is well placed to accelerate shareholder value.
Our key inhaled assets drive our base of recurring revenues. In addition to our core focus in airways diseases, Vectura has a number of legacy oral and non-inhaled products that generate revenue.
Our key inhaled assets drive our base of recurring revenues
In addition to our core focus in airways diseases, Vectura has a number of legacy oral and non-inhaled products that generate revenue.
Board and Leadership team
Our Board members are committed to a clear, strategic vision for the Group.
Skyepharma is part of the Vectura Group of Companies
We are one of the few companies globally with the expertise to deliver the most complex products.
Our formulation technologies seek to achieve state-of-the-art inhaled delivery of dry powders.
Leveraging our uniquely integrated formulation, device and development capabilities to deliver value.
Unique range of proprietary devices offering tailored drug delivery options and patient choice.
Inhalation technology FAVORITE™: Flow And Volume Regulated Inhalation Technology
Our wide partnership base enables us to create the best outcomes for programmes and patients.
Our investor centre where you can find the latest financial information.
Our success ensures that we will deliver long-term value for our shareholders and for society.
Stock exchange announcements
Financial news and announcements.
RNS email alerts
Subscribe and keep up-to-date with the latest financial information.
Presentations and webcasts
A selection of presentations and webcasts.
Our financial year, previous successes and clear strategies for the future
Our commitment to the principles of good governance enables us to deliver a clear refocused investment strategy.
Financial calendar and events
Meetings and events throughout the financial year.
Meetings and voting
The date and proposed resolutions for our next general meeting.
Share price information
Our up-to-the-minute share price as well as historical information.
Essential information for our shareholders.
Managing your shares
Important information on how to handle your shares.
Warning to shareholders
Share fraud warning and helpful numbers.
Analysts commenting on Vectura.
Vectura Group plc recommended All Share Merger with Skyepharma PLC
On 10 June 2016, an all-share merger of Vectura and Skyepharma PLC was completed.
Historical share offerings
Essential information for any shareholders in possession of historical shares.
News and media
The latest headlines from Vectura Group.
The latest updates and press releases from Vectura Group.
Connect and discover more about us, our people and our culture.
Our latest innovations and success stories.
Global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio
[ description missing ]
Breelib™ meets iloprost
A modern nebuliser for an established drug
A large and untapped US market with few new entrants into this complex space
New product creation – from paper to market
We take products from a blank piece of paper right the way through to market, but the patient is always at the centre of what we do
Bringing nebuliser device and formulation together
Our unique capabilities mean "all the pieces of the jigsaw fit"
Fundraising for AsthmaUK
Vectura deploys its international pedal power for charity
Vectura Group Interim Results for H1 2018
Rising to the challenge of developing inhaled generic medicines
And why Vectura is well placed to innovate in this space
Pre-close trading update confirms good progress against 2018 goals
The Group expects revenue to be in line with, and EBITDA to be materially above, current market consensus expectations
A selection of resources introducing our business, culture and people.
Media contacts for Vectura
We create a dynamic and rewarding place to work with clear development opportunities.
The latest updates